We’ve developed hundreds of medicines across all dosage forms. Along the way, we’ve earned our reputation as a trusted leader in highly complex medicines. Our pipeline centers on meeting unmet needs, filling drug shortages and opening access to the world’s most advanced and critical medicines.
As of October 2025, we have 69 ANDAs pending (64% are complex products) and 44 additional products in development (95% are complex products).
Data as of October 2025. All trademarks listed below are the property of their respective owners.
Launch Date / Anticipated Launch Date
Launch Date / Anticipated Launch Date
Therapeutic Area - Gastroenterology
Referenced Brand - Asacol® HD
Dosage Form - Tablet
Approval - Q1’25
Launch - Q1’25
Therapeutic Area - Oncology
Referenced Brand - Afinitor®
Dosage Form - Tablet
Approval - Q1’25
Launch - Q1’25
Launch Date / Anticipated Launch Date
Therapeutic Area - Emergency/Critical Care
Referenced Brand - Adrenalin®
Dosage Form - SDV/MDV/PFS
Approval - Q4’25/Q1’26*
Launch - Q4’25/Q1’26
Therapeutic Area - Opthalmology
Referenced Brand - Pred-Forte®
Dosage Form - Ophthalmic
Approval - Q2’25
Launch - Q4’25
Therapeutic Area - Psychiatry
Referenced Brand - Risperdal Consta®
Dosage Form - Vial
Approval - Q3’25
Launch - Q4’25
Launch Date / Anticipated Launch Date
Therapeutic Area - Diagnostic
Referenced Brand - Omnipaque®
Dosage Form - Vial
Approval - Q4’25*
Launch - Q1’26
Therapeutic Area - Hematology
Referenced Brand - Promacta®
Dosage Form - Tablet
Approval - Q1’26*
Launch - Q1’26
Therapeutic Area - Emergency/Critical Care
Referenced Brand - Adrenalin®
Dosage Form - SDV/MDV/PFS
Approval - Q4’25/Q1’26*
Launch - Q4’25/Q1’26
Therapeutic Area - Oncology
Referenced Brand - Somatuline® Depot
Dosage Form - PFS
Approval - Q1’26*
Launch - Q1’26
Therapeutic Area - Oncology
Referenced Brand - Revlimid®
Dosage Form - Capsule
Approval - Q1’25
Launch - Q1’26
Therapeutic Area - Oncology
Referenced Brand - Romidepsin
Dosage Form - Vial
Approval - Q1’26*
Launch - Q1’26
Therapeutic Area - Ophthalmology
Referenced Brand - Restasis®
Dosage Form - Ophthalmic
Approval - Q4’25*
Launch - Q1’26
Therapeutic Area - Respiratory
Referenced Brand - QVAR®
Dosage Form - Inhalation
Approval - Q4’25
Launch - Q1’26
Launch Date / Anticipated Launch Date
Therapeutic Area - Gastroenterology
Referenced Brand - Xifaxan®
Dosage Form - Tablet
Approval - Q1’25
Launch - Undisclosed
Therapeutic Area - Immunology/Allergy
Referenced Brand - XOLAIR®
Dosage Form - PFS
Approval - Q3’26*
Launch - Undisclosed
Therapeutic Area - Neurology
Referenced Brand - Xyrem®
Dosage Form - Oral solution
Approval - Q3’25
Launch - Undisclosed
Therapeutic Area - Ophthalmology
Referenced Brand - Lumigan®
Dosage Form - Ophthalmic
Approval - Q3’25
Launch - Undisclosed
Therapeutic Area - Osteoporosis/Bone Cancer
Referenced Brand - PROLIA® & XGEVA®
Dosage Form - Vial
Approval - Q4’25*
Launch - Undisclosed
Therapeutic Area Respiratory
Referenced Brand - ProAir® HFA
Dosage Form - Inhalation
Approval - Q4’25*
Launch - Undisclosed
Note: Selected new product launches listed. Additional opportunities not disclosed. All trademarks are the property of their respective owners. PFS = Prefilled Syringe; MDV = Multiple-dose vial; RTU = Ready-to-use; SDV = Single-dose vial; BLA = Biologics License Application.
*Not yet approved, estimated approval date
Corporate
India